Non-steroidal and non-cytotoxic therapies for nephrotic syndrome

Nephrology Dialysis Transplantation

Volumn 23, Issue 6, 2008, Pages 1793-1796

  Coppo, Rosanna ^a,b  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Cyclosporine; Mycophenolate mofetil; Nephrotic syndrome; Rituximab; Tacrolimus

Indexed keywords

CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS;

DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; FOCAL GLOMERULOSCLEROSIS; HUMAN; MEMBRANOUS GLOMERULONEPHRITIS; MONOTHERAPY; NEPHROTIC SYNDROME; NEPHROTOXICITY; NOTE; PRIORITY JOURNAL; PROTEINURIA; REPEATED DRUG DOSE; RISK BENEFIT ANALYSIS;

ADRENOCORTICOTROPIC HORMONE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOPHENOLIC ACID; NEPHROTIC SYNDROME; PROGNOSIS; RISK ASSESSMENT; TACROLIMUS; TREATMENT OUTCOME;

EID: 44449130142     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn211     Document Type: Note

References (32)

1. Korbet SM. Clinical picture and outcome of primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 1999; 14(Suppl 3): 68-73
2. Filler G, Young E, Geler P et al. Is there really an increase in non-minimal change nephritic syndrome in children? Am J Kidney Dis 2003; 42: 1107-1113
3. Hodson E, Willis N, Craig J. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev 2008; 23: CD002290
4. Meyrier A. Nephrotic focal segmental glomerulosclerosis in 2004: an update. Nephrol Dial Transplant 2004; 19: 2437-2444
5. Ponticelli C, Passerini P. Treatment of membranous nephropathy. Nephrol Dial Transplant 2001; 16(Suppl 5): 8-10
6. Perna A, Schieppati A, Zamora J et al. Immunosuppressive treatment for idiopathic membranous nephropathy. Am J Kidney Dis 2004; 44: 385-401
7. Hodson EM, Habashy D, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 2006; 19: CD003594
8. Korbet SM. Treatment of primary focal segmental glomerulosclerosis. J Am Soc Nephrol 2002; 62: 2301-2310
9. Ponticelli C, Passerini P, Salvadori M et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006; 47: 233-240.
10. Cattran DC, Alexopoulos E, Heering P et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int 2007; 72: 1429-1447
11. Cattran DC, Appel GB, Hebert LA et al. North America Nephrotic Syndrome Study Group. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001; 59: 1484-1490
12. Ghiggeri GM, Catarsi P, Scolari F et al. Cyclosporine in patients with steroid-resistent nephritic syndrome: an open-label, nonrandomized, retrospective study. Clin Ther 2004; 26: 1411-1418
13. Goumenos A, Katopodis K, Passadakis P et al. Corticosteroids and cyclosporin A in idiopathic membranous nephropathy: higher remission rate of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs. Am J Nephrol 2007; 27: 2296-2319
14. Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephritic syndrome. Pediatr Nephrol 2004; 19: 281-287
15. Westhoff TH, Schmidt S, Zidek W et al. Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome. Clin Nephrol 2006; 65: 393-400
16. Segarra A, Villa J, Poe L et al. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 2002; 17: 655-662
17. Sinha MD, MacLeod R, Rigby E et al. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant 2006; 21: 1848-1854
18. Yu L, Heng L. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. Nephrol Dial Transplant 2007; doi: 10.1093/ndt/gfm637
19. Barrio M, Fernandz Juares V, Luno.J. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. J Kidney Int 2007; 71: 924-930
20. Bagga A, Hari P, Moudgil A et al. Mycophenolate mofetil and prednisone therapy in children with steroid-dependent nephritic syndrome. Am J Kidney Dis 2003; 42: 1114-1120
21. Cattran DC, Wang MM, Appel g et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004; 62: 405-411
22. Jha V, Nayagam L, Senthil L et al. MMF or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant 2007; doi: 10.1093/ndt/gfm538
23. Ballarin J, Poveda R, Ara J et al. Treatment of idiopathic membranous nephropathy with combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol Dial Transpl 2007; 22: 3196-3201
24. Dantal J, Bigot E, Bogers W et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330: 7-14
25. Nozu K et al. Rituximab treatment for posttransplant lymphoproliferative disorder induces complete remission of recurrent nephritic syndrome. Pediatr Nephrol 2005; 20: 1660-1669
26. Francois H, Daugas E, Bensman A et al. Unexpected efficacy of rituximab in multirelapsing minimal change nephritic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis 2007; 49: 158-161
27. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006; 354: 1961-1963
28. Gilbert RD, Hulse E, Ridgen S. Rituximab therapy for steroid-dependent minimal change nephritic syndrome. Pediatr Nephrol 2006; 21: 1698-1700
29. Shahed Ahmed M, Wong CF. Rituximab and nephrotic syndrome: a new therapeutic hope? Nephrol Dial Transplant 2008; 23: 11-17
30. Ruggenenti P et al. Rituximab in idiopathic membranous nephropathy: a one year prospective study. J Am Soc Nephrol 2003; 14: 1851-1857
31. Fervenza FC, Cosio FG, Erickson SB et al. Rituximab treatment of idioapthic membranous nephropathy. Kidney Int 2007; 73: 117-125
32. Cravedi P, Ruggenenti P, Sghirlanzoni MC et al. Table titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007; 2: 932-937